<DOC>
	<DOCNO>NCT01478529</DOCNO>
	<brief_summary>A study evaluate much active compound mirabegron come blood circulation give controlled-release pill compare give intravenously .</brief_summary>
	<brief_title>A Study Find Out How Much Mirabegron Gets Into Body After Dosing With Tablet Formulation</brief_title>
	<detailed_description>All participant receive oral iv formulation , separate washout period . Treatment arm A receive low dose mirabegron ; Treatment arm B receive high dose mirabegron .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body weight 60.0 100.0 kg Body Mass Index 18.0 30.0 kg/m2 Known suspected hypersensitivity βadrenergic receptor agonists constituent formulation use Clinically significant elevation serum creatinine liver enzymes evidence creatinine &gt; 150 ųmol/L ; ASAT , ALAT LDH &gt; 2x ULN ; ɣGT &gt; 3x ULN and/or abnormal serum bilirubin Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug Subjects take β blocker β agonist ( eye drop allow ) Any clinically significant history upper gastrointestinal symptom ( nausea , vomit , abdominal discomfort upset , heartburn ) 4 week prior first admission Research Unit Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , ophthalmologic , renal , hepatic , neurological , dermatological , psychiatric metabolic Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test QTcB interval &gt; 430 ( mean QTcB two measurement &gt; 430msec ) Abnormal pulse rate measurement ( &lt; 40 &gt; 90 bpm ) prestudy visit subject rest supine position 5 min . Abnormal blood pressure measurement take prestudy visit subject rest supine position 5 min follow : Systolic blood pressure &lt; 95 &gt; 160 mmHg Diastolic blood pressure &lt; 40 &gt; 90 mmHg Positive orthostatic test screening i.e . symptom dizziness , lightheadedness etc . fall &gt; 20 mmHg systolic blood pressure 2 min stand increase pulse rate ≥ 20 bpm Regular use prescribe OTC drug except paracetamol 3 g/day , 4 week prior admission Research Unit OR use drug 2 week prior first admission Research Unit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 1</keyword>
</DOC>